Home Stock

Stock Research: Veru

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Veru

NAQ:VERU US92536C1036
15
  • Value
    31
  • Growth
    26
  • Safety
    Safety
    29
  • Combined
    10
  • Sentiment
    39
  • 360° View
    360° View
    15
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Veru Inc. is a biopharmaceutical company focused on developing medicines for metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its main businesses involve drug development programs for enobosarm and sabizabulin. In the last fiscal year, the company had a market cap of $85 million, profits of $6 million, revenue of $17 million, and 210 employees.

more

ANALYSIS: With an Obermatt 360° View of 15 (better than 15% compared with alternatives), overall professional sentiment and financial characteristics for the stock Veru are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with all four indicators below average for Veru. The consolidated Value Rank has a low rank of 31 which means that the share price of Veru is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 69% of alternative stocks in the same industry. The consolidated Growth Rank also has a low rank of 26, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is lower than for 26% of competitors in the same industry. The consolidated Safety Rank has a riskier rank of 29, which means that the company has a riskier financing structure than 71% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a low rank of 39, which means that professional investors are more pessimistic about the stock than for 61% of alternative investment opportunities. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Analyst Opinions
Country USA
Industry Pharmaceuticals
Size X-Small
Website verupharma.com
Index
Veru stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
31 11 10 9
Growth
26 95 3 45
Safety
Safety
29 57 4 66
Sentiment
39 26 12 51
360° View
360° View
15 54 1 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
100 64 71 88
Opinions Change
50 83 50 50
Pro Holdings
n/a 33 1 65
Market Pulse
28 1 9 16
Sentiment
39 26 12 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
31 11 10 9
Growth
26 95 3 45
Safety Safety
29 57 4 66
Combined
10 75 1 17
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
31 1 11 33
Price vs. Earnings (P/E)
29 22 22 22
Price vs. Book (P/B)
60 47 35 62
Dividend Yield
1 1 1 1
Value
31 11 10 9
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
33 51 1 82
Profit Growth
57 53 55 1
Capital Growth
50 87 7 71
Stock Returns
10 71 5 23
Growth
26 95 3 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
39 64 44 76
Refinancing
13 78 21 71
Liquidity
73 4 13 17
Safety Safety
29 57 4 66

Similar Stocks

Discover high‑ranked alternatives to Veru and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Resideo Technologies

NYQ:REZI
Country: USA
Industry: Building Products
Size: Large
Full Stock Analysis

Peabody Energy

NYQ:BTU
Country: USA
Industry: Coal & Consumable Fuels
Size: Large
Full Stock Analysis

Innoviva

NSQ:INVA
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews